Joseph Elsherbini

Joseph Elsherbini

Auto-generated profile, based on publicly available information

Joseph Elsherbini

Department of Civil and Environmental Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2021 in Science
Verified
Journal Article
Closed access
FHFatima Aysha Hussain
Fatima Aysha Hussain
JDJavie Dubert
Javie Dubert
JEJoseph Elsherbini
Joseph Elsherbini
MMMikayla Murphy
Mikayla Murphy
DVDavid VanInsberghe
David VanInsberghe
MPMartin F. Polz
Martin F. Polz
Wild phage evolution: Bacteria possess a diversity of highly specific phage defense mechanisms that evolve rapidly and that account for a large proportion of bacterial genomes. These dynamics must be understood if phage therapy is to be seriously considered for clinical use. Hussain et al . studied a set of nearly clonal wild-caught Vibrio lentus hosts and their phage and found that the hosts segregated into two groups infected by different viruses (see the Perspective by Meaden and Fineran). Puzzlingly, both host groups have the same surface phage receptors. This apparent paradox was resolved by sequencing of the hosts, which revealed distinct suites of endogenous but mobile phage defense elements (PDEs) in the two host phenotypes. Indeed, the PDEs constitute a large fraction of the flexible noncore genome of the bacteria. This means the PDEs can evolve and transfer from cell to cell without interfering with metabolic processes required to synthesize essential cell surface molecules. —CA

21 August 2025 in bioRxiv
Verified
Preprint
Open access
JSJohnathan Shih
Johnathan Shih
SBSeth M. Bloom
Seth M. Bloom
JXJiawu Xu
Jiawu Xu
CMCaroline M. Mitchell
Caroline M. Mitchell
JEJoseph Elsherbini
Joseph Elsherbini
DKDouglas S. Kwon
Douglas S. Kwon
Live biotherapeutic products (LBPs) deliver microbial strains to modulate the host microbiota in order to promote health or treat and prevent disease. Since endogenous strains are already present, accurately evaluating LBP efficacy and mechanism of action requires distinguishing administered from endogenous strains. Although computational tools exist for inferring strains from short-read metagenomic data, few have been rigorously tested in the context of LBP treatment. Here, we assess the ability of StrainFacts, a computational tool for inferring strains from short-read metagenomic data, to estimate strain abundances and genotypes of endogenous and administered strains. We performed a simulation study of a single-strain LBP trial, modeling serial samples across a range of administered strain abundance, co-occurring endogenous strains, and sequencing depths. We found that StrainFacts accurately estimated both LBP and endogenous strain abundances and genotypes within simulated samples. We further validated methods using human vaginal microbiota samples spiked with CTV-05, the Lactobacillus crispatus strain contained in the LBP LACTIN-V, which has been shown to reduce recurrent bacterial vaginosis. Our findings demonstrate that StrainFacts can robustly assess LBP and endogenous strain colonization, abundance, and dynamics in simulated and experimental microbiota samples, supporting its utility as an analysis tool for vaginal LBP therapeutic trial data.